Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 533138 | NSE Symbol : ASTEC | ISIN : INE563J01010 | Industry : Pesticides / Agrochemicals - Indian |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-Apr-2025	23-Apr-2025	Accounts	Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 ,inter alia, to consider and approve Please find enclosed intimation of Board Meeting to be held on Wednesday, 23rd April, 2025. Please find enclosed the Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2025. Please find enclosed the Outcome of the Board Meeting held on April 23, 2025. (As Per Bse Announcement Dated on :23.04.2025)
28-Mar-2025	28-Mar-2025	Change in Directors	Please find enclosed Outcome of the Board Meeting held on 28th March, 2025.
20-Jan-2025	27-Jan-2025	Quarterly Results	Quarterly Results ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Kindly find enclosed the prior intimation of the Company. Please find enclosed intimation for conduct of Postal Ballot for seeking Approval of Shareholders for Re-appointment of Independent Director. Please find enclosed the intimation of proposed acquisition of 26% Equity shareholding in proposed Special Purpose Vehicle (As per BSE Announcement Dated on 27/01/2025)
09-Oct-2024	25-Oct-2024	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Kindly find enclosed the prior intimation of the Company. Please find enclosed outcome of the Board Meeting dated October 25, 2024 (As per BSE Announcement Dated on 25/10/2024)
18-Jul-2024	29-Jul-2024	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Intimation of Board Meeting as per Regulations 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 Kindly find enclosed the Outcome of the Board Meeting held on Monday, July 29, 2024. Kindly find enclosed the Outcome of Board Meeting held on July 29, 2024. (As Per BSE Announcement dated on 29.07.2024)
24-Apr-2024	02-May-2024	Accounts	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March 2024 after these results are reviewed by the Audit Committee. Please find enclosed outcome of Board Meeting held on 2nd May, 2024 Please find attached Audited Financial Results for the Quarter and Financial Year ended March 31, 2024 Please find enclosed intimation of resignation of Chief Financial Officer with effect from the closure of business hours on 3rd May, 2024 Please find enclosed intimation of resignation of Mr. Vijay K. Khot, Independent Director of the Company with effect from closure of business hours on 2nd May, 2024 Please find enclosed the intimation of cessation of Directorship of Mr. Vijay K. Khot, Independent Director of the Company, with effect from the closure of business hours on 2nd May, 2024. The 30th (Thirtieth) Annual General Meeting of the Company will be held on Monday, 29th July, 2024, at 4.00 p.m. (IST) by Video Conference / Other Audio Visual Mode. (As Per BSE Announcement Dated on 02/05/2024)
12-Jan-2024	25-Jan-2024	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2024 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) that the Meeting of the Board of Directors of Astec LifeSciences Limited (the Company) is scheduled to be held on Thursday 25th January 2024 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months period ended 31st December 2023 after these results are reviewed by the Audit Committee. Kindly find enclosed the Outcome of the Board Meeting held by Astec LifeSciences Limited on January 25, 2024. Kindly find enclosed the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months'' period ended December 31, 2023 approved in the Board Meeting held by Astec LifeSciences Limited on January 25, 2024. Re-appointment of Mr. Anurag Roy as the 'Whole Time Director & Chief Executive Officer' of the Company, subject to the approval of the Shareholders. (As per BSE Announcement Dated on 25/01/2024)
10-Oct-2023	27-Oct-2023	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 that the Meeting of the Board of Directors of Astec LifeSciences Limited (the Company) is scheduled to be held on Friday 27th October 2023 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2023 after these results are reviewed by the Audit Committee and the Board of Directors may also consider and approve enhancement in the existing limit of issuance of Debenture(s) or Debt Securities upto such limit as may be deemed appropriate by the Board subject to such other approval(s) as may be applicable. Kindly find enclosed Outcome of Board Meeting held on October 27, 2023 Please find enclosed outcome of Board Meeting held on October 27, 2023 (As Per BSE Announcement Dated on 27.10.2023) kindly find enclosed the copies of the newspaper publications of the unaudited financial results for the quarter and Half Year ended September 30, 2023. (As per BSE Announcement Dated on 28/10/2023)
20-Jul-2023	27-Jul-2023	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) that the Meeting of the Board of Directors of Astec LifeSciences Limited (the Company) is scheduled to be held on Thursday 27th July 2023 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June 2023 after these results are reviewed by the Audit Committee. Pursuant to Regulation 30, 33 and 52(4) of the SEBI Listing Regulations, this is to inform you that the Board of Directors of Company at its Meeting held today, i.e. July 27, 2023 has approved the Unaudited Financial Results along with the noting of the Limited Review Report of the Statutory Auditor. Kindy find enclosed the Outcome of the Board Meeting held by the Astec LifeSciences Limited on July 27, 2023. (As per BSE Announcement Dated on 27/07/2023)
21-Apr-2023	02-May-2023	Accounts	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2023 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March 2023 after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend if any on the Equity Shares of the Company for the Financial Year ended 31st March 2023. The Board of Directors has recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e., Rs.1.50 (Rupee One and Paise Fifty ) per Equity Share of Face Value of Rs.10/- (Rupees Ten Only) each for the Financial Year ended 31st March, 2023, subject to approval of the Shareholders at the ensuing 29th (Twenty Ninth) Annual General Meeting of the Company. Kindly find attached the outcome of the Board Meeting held on 2nd May, 2023. Kindly find attached the Audited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards) for the Quarter and Financial Year ended 31st March, 2023. (As Per BSE Announcement Dated on 02.05.2023)
11-Jan-2023	30-Jan-2023	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2023 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months period ended 31st December 2022 (subject to limited review by the Statutory Auditors of the Company) after these results are reviewed by the Audit Committee. ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2023 ,inter alia, to consider and approve Further to the intimation dated 11th January, 2023 regarding the Meeting of the Board of Directors of Astec LifeSciences Limited ('the Company') scheduled to be held on Monday, 30th January, 2023 to, inter alia, consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Nine Months' period ended 31st December, 2022, notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), that, at the said Meeting, the Board may also consider and approve issuance of Debentures or debt securities upto such limit as may be deemed appropriate and approved by the Board, subject to such other approval(s) as may be applicable. (As per BSE Announcement Dated on 25/01/2023) Please find attached outcome of Board Meeting held on 30th January, 2023. The Board of Directors has approved the proposal to raise funds through issuance of Non-Convertible Debentures ('NCD') for expansion and development of business operations of the Company and meeting the short term and long-term financial requirements of the Company, including but not limited to, expenditure proposed to be incurred for improving the facilities being provided in its set-up and / or meeting the working capital requirements, for an amount upto Rs.50 Crore (Rupees Fifty Crore Only). (As Per BSE Announcement dated on 30.01.2023)
20-Oct-2022	28-Oct-2022	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2022 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) that the Meeting of the Board of Directors of Astec LifeSciences Limited (the Company) is scheduled to be held on Friday 28th October 2022 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended 30th September 2022 (subject to limited review by the Statutory Auditors of the Company) after these results are reviewed by the Audit Committee. Please find attached outcome of Board Meeting held today, i.e. 28th October, 2022 Please find attached outcome of Board Meeting held today, 28th October, 2022 The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. Madhur Gundecha as the 'Chief Financial Officer' of the Company with effect from 28th October, 2022. The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. Madhur Gundecha as the 'Chief Financial Officer' of the Company with effect from 28th October, 2022. (As Per BSE Announcement Dated on 28.10.2022)
16-Jul-2022	25-Jul-2022	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2022 inter alia to consider and approve Notice is hereby given pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) that the Meeting of the Board of Directors of Astec LifeSciences Limited (the Company) is scheduled to be held on Monday 25th July 2022 to inter alia consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter ended 30th June 2022 (subject to limited review by the Statutory Auditors of the Company) after these results are reviewed by the Audit Committee. This intimation is also made available on the website of the Company i.e. www.astecls.com Please find attached outcome of the Board Meeting held today i.e. on 25th July, 2022. Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30th June, 2022. The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee of the Board of Directors, has appointed Mr. Burjis Godrej [Director Identification Number (DIN): 08183082] as an 'Additional, Non-Executive, Non- Independent Director' of the Company with effect from 25th July, 2022. The appointment of Mr. Burjis Godrej as an 'Additional, Non-Executive, Non-Independent Director' with effect from 25th July, 2022, is subject to approval of the Shareholders of the Company. Seeking Approval of the Shareholders by way of Postal Ballot for appointment of Mr. Burjis Godrej as 'Non-Executive Non-Independent Director' of the Company. (As per BSE Announcement Dated on 25/07/2022)
25-Apr-2022	02-May-2022	Accounts	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2022 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results for the Quarter and Financial Year ended 31st March 2022 after these results are reviewed by the Audit Committee and to consider recommendation of Final Dividend if any on the Equity Shares of the Company for the Financial Year ended 31st March 2022. The Board of Directors at its Meeting held on 2nd May, 2022 has recommended Final Dividend of 15% (Fifteen per cent) on the Equity Share Capital of the Company, i.e. Rs.1.50 (Rupee One and Paise Fifty) per Equity Share of Face Value of Rs.10/- (Rupees Ten Only) for the Financial Year ended 31st March, 2022, subject to approval of the Shareholders at the ensuing 28th (Twenty Eighth) Annual General Meeting of the Company. Please find attached outcome of the Board Meeting held today i.e. on 2nd May, 2022 The Board of Astec LifeSciences Limited has noted the resignation of Mr. Rakesh Dogra (DIN: 07334098) from the position of 'Non-Executive, Non-Independent Director' of the Company with effect from 2nd May, 2022. (As Per BSE Announcement Dated on 02.05.2022)
18-Jan-2022	25-Jan-2022	Quarterly Results	ASTEC LIFESCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2022 inter alia to consider and approve the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months period ended 31st December 2021 (subject to limited review by the Statutory Auditors of the Company) after these results are reviewed by the Audit Committee. Please find attached outcome of the Board Meeting held today i.e. on 25th January, 2022 The Board of Directors has approved amendment in the 'Policy on Materiality of Related Party Transactions and on Dealing with Related Party Transactions' of the Company. (As Per BSE Announcement dated on 25.01.2022)

1 2

LOGIN HERE

Astec Lifesciences Ltd

Board Meeting